

Optum Coding for Coronavirus (COVID-19)

Below is an overview of and industry guidance for coding changes related to the 2019 novel coronavirus (COVID-19). Optum is committed to ensuring that you have the information you need to effectively and efficiently address COVID-19 from a medical coding, billing, and reimbursement perspective. We have compiled information from the World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS), American Medical Association (AMA), and the Centers for Medicare and Medicaid Services (CMS), so you can easily access the most up-to-date medical code detail and effective dates in one convenient place. Use the following to link to the sections within this document:

[CPT Codes](#) | [HCPCS Codes](#) | [Vaccine Table](#) | [Monoclonal Antibodies](#) | [ICD-10-CM/ICD-10-PCS](#) | [Vaccines - Dental](#)

CPT Codes

The American Medical Association (AMA) has issued the following codes to the CPT Procedure Coding System. Additional information can be found at https://www.ama-assn.org/practice-management/cpt .				
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) Related CPT Codes				
Code	Descriptor	Effective Date	End Date	Location in Optum coding product, <i>Current Procedural Coding Expert</i>
86318	Immunoassay for infectious agent antibody(ies), qualitative or semiquantitative, single-step method (eg, reagent strip);	04/10/2020	N/A	N/A
86769	Antibody; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])	04/10/2020	N/A	N/A
87426	Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (eg, SARS-CoV, SARS-CoV-2 [COVID-19])	01/01/2022	N/A	N/A
87428	Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (eg, SARS-CoV, SARS-CoV-2 [COVID-19]) and influenza virus types A and B	11/10/2020	N/A	N/A
87635	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), amplified probe technique	03/13/2020	N/A	N/A
87636	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique	10/06/2020	N/A	N/A
87637	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique	10/06/2020	N/A	N/A
#86328	Immunoassay for infectious agent antibody(ies), qualitative or semiquantitative, single step method (eg, reagent strip); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])	04/10/2020	N/A	Resequenced code. See code following 86318.
#86408	Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]); screen	08/10/2020	N/A	Resequenced code. See code following 86382.
#86409	Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]); titer	08/10/2020	N/A	Resequenced code. See code following 86382.
#86413	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) antibody, quantitative	09/08/2020	N/A	Resequenced code. See code following resequenced code 86409.
#87811	Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])	10/06/2020	N/A	Resequenced code. See code following 87807.
#87913	Infectious agent genotype analysis by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), mutation identification in targeted region(s)	02/21/2022	N/A	Resequenced code. See code following 87902.
#91300	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use	12/11/2020	N/A	Resequenced code. See code before 90476.

#91301	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, for intramuscular use	12/18/2020	N/A	Resequenced code. See code before 90476.
#91302	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10 ¹⁰ viral particles/0.5mL dosage, for intramuscular use	12/17/2020	N/A	Resequenced code. See code before 90476.
#91303	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 ¹⁰ viral particles/0.5mL dosage, for intramuscular use	02/27/2021	N/A	Resequenced code. See code before 90476.
#91304	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage, for intramuscular use	05/04/2021	N/A	Resequenced code. See code before 90476.
#91305	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	10/29/2021	N/A	Resequenced code. See code before 90476.
#91306	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use	10/20/2021	N/A	Resequenced code. See code before 90476.
#91307	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	10/29/2021	N/A	Resequenced code. See code before 90476.
#91308	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	02/01/2022	N/A	Resequenced code. See code before 90476.
#91309	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use	3/7/2022	N/A	Resequenced code. See code before 90476.
#91310	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, monovalent, preservative free, 5 mcg/0.5 mL dosage, adjuvant AS03 emulsion, for intramuscular use	4/26/2022	N/A	Resequenced code. See code before 90476.
99072	Additional supplies, materials, and clinical staff time over and above those usually included in an office visit or other nonfacility service(s), when performed during a Public Health Emergency, as defined by law, due to respiratory-transmitted infectious disease		N/A	N/A
#0001A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; first dose	12/11/2020	N/A	Resequenced code. See code following 90474.
#0002A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose	12/11/2020	N/A	Resequenced code. See code following 90474.
#0003A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; third dose	08/12/2021	N/A	Resequenced code. See code following 90474.
#0004A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; booster dose	09/22/2021	N/A	Resequenced code. See code following 90474.
#0011A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; first dose	12/18/2020	N/A	Resequenced code. See code following 90474.
#0012A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; second dose	12/18/2020	N/A	Resequenced code. See code following 90474.

#0013A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; third dose	08/12/2021	N/A	Resequenced code. See code following 90474.
#0021A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10 ¹⁰ viral particles/0.5mL dosage; first dose	12/17/2020	N/A	Resequenced code. See code following 90474.
#0022A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10 ¹⁰ viral particles/0.5mL dosage; second dose	12/17/2020	N/A	Resequenced code. See code following 90474.
#0031A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 ¹⁰ viral particles/0.5mL dosage; single dose	02/27/2021	N/A	Resequenced code. See code following 90474.
#0051A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; first dose	10/29/2021	N/A	Resequenced code. See code following resequenced code 0004A.
#0052A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; second dose	10/29/2021	N/A	Resequenced code. See code following resequenced code 0004A.
#0053A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; third dose	10/29/2021	N/A	Resequenced code. See code following resequenced code 0004A.
#0054A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; booster dose	09/03/2021	N/A	Resequenced code. See code following resequenced code 0004A.
#0064A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, booster dose	10/20/2021	N/A	Resequenced code. See code following resequenced code 0013A.
#0071A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose	10/29/2021	N/A	Resequenced code. See code following resequenced code 0054A.
#0072A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose	10/29/2021	N/A	Resequenced code. See code following resequenced code 0054A.
#0073A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose	01/03/2022	N/A	Resequenced code. See code following resequenced code 0054A.
#0074A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; booster dose	04/26/2022	N/A	Resequenced code. See code following resequenced code 0054A.
#0094A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, booster dose	03/29/2022	N/A	Resequenced code. See code following resequenced code 0064A.
0104A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, monovalent, preservative free, 5 mcg/0.5 mL dosage, adjuvant AS03 emulsion, booster dose	04/26/2022	N/A	N/A
0202U	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected	05/20/2020	N/A	N/A

0223U	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected	06/25/2020	N/A	N/A
0224U	Antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), includes titer(s), when performed	06/25/2020	N/A	N/A
0225U	Infectious disease (bacterial or viral respiratory tract infection) pathogen-specific DNA and RNA, 21 targets, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected	08/10/2020	N/A	N/A
0226U	Surrogate viral neutralization test (sVNT), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), ELISA, plasma, serum	08/10/2020	N/A	N/A
0240U	Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 3 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B), upper respiratory specimen, each pathogen reported as detected or not detected	10/06/2020	N/A	N/A
0241U	Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 4 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B, respiratory syncytial virus [RSV]), upper respiratory specimen, each pathogen reported as detected or not detected	10/06/2020	N/A	N/A
Notes:				
# Resequenced Code ✎ Non-FDA Drug				
A CPT code and HCPCS code should not be reported together for COVID-19 testing, vaccines, or monoclonal antibody therapy. Providers should contact third-party payer(s) for their guidance on whether to report a CPT or a HCPCS code, as well as for retroactive billing and reimbursement guidelines.				
CPT © 2021 American Medical Association. All Rights Reserved. CPT is a registered trademark of the American Medical Association.				

HCPCS Codes

The Centers for Medicare and Medicaid Services (CMS) has issued the following codes to the HCPCS Procedure Coding System. Additional information can be found at https://www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets/HCPCS-Quarterly-Update .				
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) Related HCPCS Codes				
Code	Descriptor	Effective Date	End Date	
C9803	Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), any specimen source	03/01/2020	N/A	
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), any specimen source	03/01/2020	N/A	
G2024	Specimen collection for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) from an individual in a SNF or by a laboratory on behalf of a HHA, any specimen source	03/01/2020	N/A	
J0248	Injection, remdesivir, 1 mg	12/23/2021	N/A	
M0201	COVID-19 vaccine administration inside a patient's home; reported only once per individual home, per date of service, when only COVID-19 vaccine administration is performed at the patient's home	05/26/2021	N/A	
M0220	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known SARS-CoV-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available COVID-19 vaccine is not recommended due to a history of severe adverse reaction to a COVID-19 vaccine(s) and/or COVID-19 vaccine component(s), includes injection and post administration monitoring	12/08/2021	N/A	
M0221	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known SARS-CoV-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available COVID-19 vaccine is not recommended due to a history of severe adverse reaction to a COVID-19 vaccine(s) and/or COVID-19 vaccine component(s), includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the COVID-19 public health emergency	12/08/2021	N/A	
M0222	Intravenous injection, bebtelovimab, includes injection and post administration monitoring	02/11/2022	N/A	
M0223	Intravenous injection, bebtelovimab, includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the COVID-19 public health emergency	02/11/2022	N/A	
M0239	Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring	11/10/2020	4/17/2021	

M0240	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab, includes infusion or injection and post administration monitoring, subsequent repeat doses	07/30/2021	N/A
M0241	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab, includes infusion or injection, and post administration monitoring in the home or residence. This includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency, subsequent repeat doses	07/30/2021	N/A
M0243	Intravenous infusion, casirivimab and imdevimab, includes infusion and post administration monitoring	11/21/2020	N/A
M0244	Intravenous infusion, casirivimab and imdevimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the COVID-19 public health emergency	05/6/2021	N/A
M0245	Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring	02/09/2021	N/A
M0246	Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the COVID-19 public health emergency	05/06/2021	N/A
M0247	Intravenous infusion, sotrovimab, includes infusion and post administration monitoring	05/26/2021	N/A
M0248	Intravenous infusion, sotrovimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the COVID-19 public health emergency	05/26/2021	N/A
M0249	Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, includes infusion and post administration monitoring, first dose	06/24/2021	N/A
M0250	Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, includes infusion and post administration monitoring, second dose	06/24/2021	N/A
Q0220	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known SARS-CoV-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available COVID-19 vaccine is not recommended due to a history of severe adverse reaction to a COVID-19 vaccine(s) and/or COVID-19 vaccine component(s), 300 mg	12/08/2021	N/A
Q0222	Injection, bebtelovimab, 175 mg	02/11/2022	N/A
Q0239	Injection, bamlanivimab-xxxx, 700 mg	11/10/2020	4/17/2021
Q0240	Injection, casirivimab and imdevimab, 600 mg	07/30/2021	N/A
Q0243	Injection, casirivimab and imdevimab, 2400 mg	11/21/2020	N/A
Q0245	Injection, bamlanivimab and etesevimab, 2100 mg	02/09/2021	N/A
Q0247	Injection, sotrovimab, 500 mg	05/26/2021	N/A
Q0249	Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, 1 mg	06/24/2021	N/A
U0001	CDC 2019 Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel	02/04/2020	N/A
U0002	2019-nCoV coronavirus, SARS-CoV-2/2019-nCoV (COVID-19), any technique, multiple types or subtypes (includes all targets), non-CDC	02/04/2020	N/A
U0003	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), amplified probe technique, making use of high throughput technologies as described by CMS-2020-01-R	04/14/2020	N/A
U0004	2019-nCoV coronavirus, SARS-CoV-2/2019-nCoV (COVID-19), any technique, multiple types or subtypes (includes all targets), non-CDC, making use of high throughput technologies as described by CMS-2020-01-R	04/14/2020	N/A
U0005	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), amplified probe technique, CDC or non-CDC, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either HCPCS code U0003 or U0004) as described by CMS-2020-01-R2	01/01/2021	N/A
<p><i>A CPT code and HCPCS code should not be reported together for COVID-19 testing, vaccines, or monoclonal antibody therapy. Providers should contact third-party payer(s) for their guidance on whether to report a CPT or a HCPCS code, as well as for retroactive billing and reimbursement guidelines.</i></p>			

Vaccine Table

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) Vaccine and Administration Codes								
<p>The following table provides a link between each individual severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine code and its corresponding vaccine administration code, along with the vaccine manufacturer name, vaccine name, National Drug Code (NDC) Labeler Product ID number(s), the recommended interval between vaccine doses, and the effective date. These resequenced codes are located in the Medicine section. Additional instructional notes can be found with the codes in the appropriate code ranges or at https://www.ama-assn.org/practice-management/cpt/covid-19-cpt-vaccine-and-immunization-codes. Information regarding FDA EUA processes and dates can be found at https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#vaccines.</p>								
Vaccine Code	Long Descriptor	Administration Code(s)	Manufacturer	Vaccine Name(s)	NDC 10/ NDC 11 Labeler Product ID (vial)	Dosing Interval	Location in Optum coding products	Effective Date
#91300	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use	0001A (1st dose) 0002A (2nd dose) 0003A (3rd dose) 0004A (booster dose)	Pfizer, Inc	Pfizer-BioNTech COVID-19 Vaccine; Comirnaty	59267-1000-1 59267-1000-01	1st to 2nd dose: 21 days 2nd to 3rd dose: 28 or more days Booster: See FDA/CDC Guidance	See code before 90476.	12/11/2020
#91305	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	#0051A (1st dose) #0052A (2nd dose) #0053A (3rd dose) #0054A (booster dose)	Pfizer, Inc	Pfizer-BioNTech COVID-19 Vaccine	59267-1025-1 59267-1025-01	1st to 2nd dose: 21 days 2nd to 3rd dose: 28 or more days Booster: See FDA/CDC Guidance	See code before 90476.	10/29/2021
#91307	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	#0071A (1st dose) #0072A (2nd dose) #0073A (3rd dose)	Pfizer, Inc	Pfizer-BioNTech COVID-19 Vaccine	59267-1055-1 59267-1055-01	1st to 2nd dose: 21 days	See code following resequenced code 91305.	10/29/2021
#91308	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	0081A (1st dose) 0082A (2nd dose)	Pfizer, Inc	Pfizer-BioNTech COVID-19 Vaccine	59267-0078-1 59267-0078-01 59267-0078-4 59267-0078-04	1st to 2nd dose: 21 days	See code before 90476.	02/01/2022
#91301	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, for intramuscular use	0011A (1st dose) 0012A (2nd dose) 0013A (3rd dose)	Moderna, Inc	Moderna COVID-19 Vaccine	80777-273-10 80777-0273-10	1st to 2nd dose: 28 days 2nd to 3rd dose: 28 or more days See FDA/CDC Guidance	See code before 90476.	12/18/2020

#91306	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use	#0064A (booster dose)	Moderna, Inc	Moderna COVID-19 Vaccine	80777-273-10 80777-0273-10	See FDA/CDC Guidance	See code before 90476.	10/20/2021
# 91309	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use	#0094A (booster dose)	Moderna, Inc	Moderna COVID-19 Vaccine	80777-275-05 80777-0275-05	See FDA/CDC Guidance	See code before 90476.	03/29/2022
# 91302	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10 ^{>10</sup> viral particles/0.5mL dosage, for intramuscular use}	0021A (1st dose) 0022A (2nd dose)	AstraZeneca, Plc	AstraZeneca COVID-19 Vaccine	0310-1222-10 00310-1222-10	28 days	See code before 90476.	02/27/2021
#91303	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 ^{>10</sup> viral particles/0.5mL dosage, for intramuscular use}	0031A (single dose)	Janssen	Janssen COVID-19 Vaccine	59676-580-05 59676-0580-05	N/A	See code before 90476.	02/27/2021
# 91304	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage, for intramuscular use	0041A (1st dose) 0042A (2nd dose)	Novavax, Inc	Novavax COVID-19 Vaccine	80631-100-01 80631-1000-01	21 days	See code before 90476.	05/04/2021
# 91310	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, monovalent, preservative free, 5 mcg/0.5 mL dosage, adjuvant AS03 emulsion, for intramuscular use	0104A (booster dose)	Sanofi Pasteur	Sanofi Pasteur COVID-19 Vaccine	49281-618-20 49281-0618-20	See FDA/CDC Guidance	See code before 90476.	04/26/2022

Notes: # Resequenced Code 91309 Non-FDA Drug

COVID-19 vaccine drug codes [91300, 91301, 91302, 91303, 91304, 91305, 91306, 91307, 91308, 91309, 91310] are exempt from reporting with modifier 51.

COVID-19 vaccine administration codes 0001A-0004A, 0011A-0013A, 0021A-0022A, 0031A, 0041A-0042A, [0051A-0054A], [0064A], [0071A-0074A], [0081A-0082A], [0094A], and 0104A should be reported with vaccine codes [91300, 91301, 91302, 91303, 91304, 91305, 91306, 91307, 91308, 91309] [ITAL]only[END ITAL]. All other vaccines should be reported with [90460-90461], 90476-90749. COVID-19 vaccine administration codes should not be reported with other immunization administration codes unless an additional vaccine/toxoid is administered during the same visit.

CPT © 2021 American Medical Association. All Rights Reserved. CPT is a registered trademark of the American Medical Association.

Monoclonal Antibodies

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) Monoclonal Antibody and Administration Codes

The following table provides a link between each individual severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) monoclonal antibody code and its corresponding administration code(s), along with the manufacturer name, brand name (when available), National Drug Code (NDC) Labeler Product ID number(s), and the effective date. Additional instructional notes can be found with the codes in the appropriate code ranges or at <https://www.cms.gov/medicare/covid-19/monoclonal-antibody-covid-19-infusion>. Information regarding FDA EUA processes and dates can be found at <https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#covid19drugs>.

Code	Long Descriptor	Administration Code(s)	Manufacturer	Brand Name (When Available)	NDC 10/NDC 11 Labeler Product ID (vial)	Effective Date
J0248	Injection, remdesivir, 1 mg	96365 96366	Gilead	Veklury	61958-2901-1 61958-2901-2 61958-2902-2	12/23/2021
Q0220	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known SARS-CoV-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available COVID-19 vaccine is not recommended due to a history of severe adverse reaction to a COVID-19 vaccine(s) and/or COVID-19 vaccine component(s), 300 mg	M0220 M0221	AstraZeneca	Evusheld	0310-7442-02	12/08/2021
Q0222	Injection, bebtelovimab, 175 mg	M0222 M0223	Eli Lilly	N/A	Not Available	02/11/2022
Q0239	Injection, bamlanivimab-xxxx, 700 mg	M0239	Eli Lilly	N/A	00002-7910-01	EUA revoked 04/15/2021 when administered alone
Q0240	Injection, casirivimab and imdevimab, 600 mg	M0240 M0241	Regeneron	REGEN-COV	61755-0026-01 61755-0024-01 61755-0025-01 61755-0027-01 61755-0039-01 61755-0035-02 61755-0036-08	07/30/2021
Q0243	Injection, casirivimab and imdevimab, 2400 mg	M0243 M0244	Regeneron	REGEN-COV	61755-0024-01 61755-0026-01 61755-0025-01 61755-0027-01 61755-0039-01 61755-0035-02 61755-0036-08	05/06/2021
Q0244	Injection, casirivimab and imdevimab, 1200 mg	M0243 M0244	Regeneron	REGEN-COV	61755-0039-01 61755-0039-01 61755-0035-02 61755-0036-08	06/03/2021
Q0245	Injection, bamlanivimab and etesevimab, 2100 mg	M0245 M0246	Eli Lilly	N/A	00002-7910-01 00002-7950-01	05/06/2021
Q0247	Injection, sotrovimab, 500 mg	M0247 M0248	GlaxoSmithKline	N/A	00173-0901-86	05/26/2021
Q0249	Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, 1 mg	M0249 M0250	Genentech	Actemra	50242-0135-01 50242-0136-01 50242-0137-01	06/24/2021

ICD-10-CM and ICD-10-PCS Codes

The Centers for Disease Control and Prevention's (CDC) National Center for Health Statistics (NCHS), the federal agency responsible for maintaining the International Statistical Classification of Diseases and Related Health Problems, 10th Revision, Clinical Modification (ICD-10-CM) in the United States, implemented the following ICD-10-CM codes:

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) Related ICD-10-CM Codes

Code	Description	Effective Date
J12.82	Pneumonia due to coronavirus disease 2019	01/01/2021
M35.81	Multisystem inflammatory syndrome	01/01/2021
U07.1	COVID-19	04/01/2020
U09.9	Post COVID-19 condition, unspecified	10/01/2021
Z11.52	Encounter for screening for COVID-19	01/01/2021
Z20.822	Contact with and (suspected) exposure to COVID-19	01/01/2021
Z28.310	Unvaccinated for COVID-19	04/01/2022
Z28.311	Partially vaccinated for COVID-19	04/01/2022
Z86.16	Personal history of COVID-19	01/01/2021

The Centers for Medicare and Medicaid Services (CMS) has issued the following procedure codes to the International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS). These codes describe the introduction or infusion of therapeutics or current treatments used to manage COVID-19 patients. These codes do not affect MS-DRG assignment.

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) Related ICD-10-PCS Codes

Code	Description	Effective Date
XW013F5	Introduction of Other New Technology Therapeutic Substance into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5	08/01/2020
XW013H6	Introduction of Other New Technology Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6	01/01/2021
XW013K6	Introduction of Leronlimab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6	01/01/2021
XW013S6	Introduction of COVID-19 Vaccine Dose 1 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6	01/01/2021
XW013T6	Introduction of COVID-19 Vaccine Dose 2 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6	01/01/2021
XW013U6	Introduction of COVID-19 Vaccine into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6	01/01/2021
XW013V7	Introduction of COVID-19 Vaccine Dose 3 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7	04/01/2022
XW013W7	Introduction of COVID-19 Vaccine Booster into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7	04/01/2022
XW023X7	Introduction of Tixagevimab and Cilgavimab Monoclonal Antibody into Muscle, Percutaneous Approach, New Technology Group 7	04/01/2022
XW023Y7	Introduction of Other New Technology Monoclonal Antibody into Muscle, Percutaneous Approach, New Technology Group 7	04/01/2022
XW023S6	Introduction of COVID-19 Vaccine Dose 1 into Muscle, Percutaneous Approach, New Technology Group 6	01/01/2021
XW023T6	Introduction of COVID-19 Vaccine Dose 2 into Muscle, Percutaneous Approach, New Technology Group 6	01/01/2021
XW023U6	Introduction of COVID-19 Vaccine into Muscle, Percutaneous Approach, New Technology Group 6	01/01/2021
XW023V7	Introduction of COVID-19 Vaccine Dose 3 into Muscle, Percutaneous Approach, New Technology Group 7	04/01/2022
XW023W7	Introduction of COVID-19 Vaccine Booster into Muscle, Percutaneous Approach, New Technology Group 7	04/01/2022
XW033E5	Introduction of Remdesivir Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 5	08/01/2020
XW033E6	Introduction of Etesevimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6	01/01/2021
XW033F5	Introduction of Other New Technology Therapeutic Substance into Peripheral Vein, Percutaneous Approach, New Technology Group 5	08/01/2020
XW033F6	Introduction of Bamlanivimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6	01/01/2021
XW033G5	Introduction of Sarilumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5	08/01/2020
XW033G6	Introduction of REGN-COV2 Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6	01/01/2021
XW033H5	Introduction of Tocilizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5	08/01/2020

XW033H6	Introduction of Other New Technology Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6	01/01/2021
XW033L6	Introduction of CD24Fc Immunomodulator into Peripheral Vein, Percutaneous Approach, New Technology Group 6	01/01/2021
XW043E5	Introduction of Remdesivir Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 5	08/01/2020
XW043E6	Introduction of Etesevimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6	01/01/2021
XW043F5	Introduction of Other New Technology Therapeutic Substance into Central Vein, Percutaneous Approach, New Technology Group 5	08/01/2020
XW043F6	Introduction of Bamlanivimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6	01/01/2021
XW043G5	Introduction of Sarilumab into Central Vein, Percutaneous Approach, New Technology Group 5	08/01/2020
XW043G6	Introduction of REGN-COV2 Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6	01/01/2021
XW043H5	Introduction of Tocilizumab into Central Vein, Percutaneous Approach, New Technology Group 5	08/01/2020
XW043H6	Introduction of Other New Technology Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6	01/01/2021
XW043L6	Introduction of CD24Fc Immunomodulator into Central Vein, Percutaneous Approach, New Technology Group 6	01/01/2021
XW0DXF5	Introduction of Other New Technology Therapeutic Substance into Mouth and Pharynx, External Approach, New Technology Group 5	08/01/2020
XW0DXM6	Introduction of Baricitinib into Mouth and Pharynx, External Approach, New Technology Group 6	01/01/2021
XW0DXR7	Introduction of Fostamatinib into Mouth and Pharynx, External Approach, New Technology Group 7	04/01/2022
XW0G7M6	Introduction of Baricitinib into Upper GI, Via Natural or Artificial Opening, New Technology Group 6	01/01/2021
XW0G7R7	Introduction of Fostamatinib into Upper GI, Via Natural or Artificial Opening, New Technology Group 7	04/01/2022
XW0H7M6	Introduction of Baricitinib into Lower GI, Via Natural or Artificial Opening, New Technology Group 6	01/01/2021
XW0H7R7	Introduction of Fostamatinib into Lower GI, Via Natural or Artificial Opening, New Technology Group 7	04/01/2022
XW13325	Transfusion of Convalescent Plasma (Nonautologous) into Peripheral Vein, Percutaneous Approach, New Technology Group 5	08/01/2020
XW14325	Transfusion of Convalescent Plasma (Nonautologous) into Central Vein, Percutaneous Approach, New Technology Group 5	08/01/2020

Vaccines - Dental

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) Vaccine and Administration Codes, Dental Providers							
The following table provides a link between each individual severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine code to the vaccine manufacturer name, vaccine name, National Drug Code (NDC) Labeler Product ID number(s), the recommended interval between vaccine doses, and the effective date. These codes are only for use within a dental practice. Additional information about these codes can be found at https://www.ada.org/publications/cdt . Information regarding FDA EUA processes and dates can be found at https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#vaccines .							
Vaccine Code	Long Descriptor	Usage Description	Manufacturer	Vaccine Name(s)	NDC 10/NDC 11 Labeler Product ID (vial)	Dosing Interval	Effective Date
D1701	Pfizer-BioNTech Covid-19 vaccine administration-first dose	SARSCOV2 COVID-19 VAC mRNA 30mcg/0.3mL IM DOSE 1	Pfizer, Inc	Pfizer-BioNTech COVID-19 Vaccine; Comirnaty	59267-1000-1 59267-1000-01	1st to 2nd dose: 21 days	1/1/2021
D1702	Pfizer-BioNTech Covid-19 vaccine administration-second dose	SARSCOV2 COVID-19 VAC mRNA 30mcg/0.3mL IM DOSE 2	Pfizer, Inc	Pfizer-BioNTech COVID-19 Vaccine; Comirnaty	59267-1000-1 59267-1000-01	1st to 2nd dose: 21 days 2nd to 3rd dose: 28 or more days	1/1/2021
D1703	Moderna Covid-19 vaccine administration-first dose	SARSCOV2 COVID-19 VAC mRNA 100mcg/0.5mL IM DOSE 1	Moderna, Inc	Moderna COVID-19 Vaccine	80777-273-10 80777-0273-10	1st to 2nd dose: 28 days	1/1/2021
D1704	Moderna Covid-19 vaccine administration-second dose	SARSCOV2 COVID-19 VAC mRNA 100mcg/0.5mL IM DOSE 2	Moderna, Inc	Moderna COVID-19 Vaccine	80777-273-10 80777-0273-10	1st to 2nd dose: 28 days 2nd to 3rd dose: 28 or more days	1/1/2021
D1705	AstraZeneca Covid-19 vaccine administration-first dose	SARSCOV2 COVID-19 VAC rS-ChAdOx1 5x1010 VP/.5mL IM DOSE 1	AstraZeneca, Plc	AstraZeneca COVID-19 Vaccine	0310-1222-10 00310-1222-10	28 days	1/1/2021
D1706	AstraZeneca Covid-19 vaccine administration-second dose	SARSCOV2 COVID-19 VAC rS-ChAdOx1 5x1010 VP/.5mL IM DOSE 2	AstraZeneca, Plc	AstraZeneca COVID-19 Vaccine	0310-1222-10 00310-1222-10	28 days	1/1/2021
D1707	Janssen Covid-19 vaccine administration	SARSCOV2 COVID-19 VAC Ad26 5x1010 VP/.5mL IM SINGLE DOSE	Janssen	Janssen COVID-19 Vaccine	59676-580-05 59676-0580-05	N/A	1/1/2021
D1708	Pfizer-BioNTech Covid-19 vaccine administration-third dose	SARSCOV2 COVID-19 VAC mRNA 30mcg/0.3mL IM DOSE 3	Pfizer, Inc	Pfizer-BioNTech COVID-19 Vaccine; Comirnaty	59267-1000-1 59267-1000-01	2nd to 3rd dose: 28 or more days	1/1/2022
D1709	Pfizer-BioNTech Covid-19 vaccine administration-booster dose	SARSCOV2 COVID-19 VAC mRNA 30mcg/0.3mL IM DOSE BOOSTER	Pfizer, Inc	Pfizer-BioNTech COVID-19 Vaccine; Comirnaty	59267-1000-1 59267-1000-01	Booster: See FDA/CDC Guidance	1/1/2022
D1710	Moderna Covid-19 vaccine administration-third dose	SARSCOV2 COVID-19 VAC mRNA 100mcg/0.5mL IM DOSE 3	Moderna, Inc	Moderna COVID-19 Vaccine	80777-273-10 80777-0273-10	See FDA/CDC Guidance	1/1/2022
D1711	Moderna Covid-19 vaccine administration-booster dose	SARSCOV2 COVID-19 VAC mRNA 50mcg/0.25mL IM DOSE BOOSTER	Moderna, Inc	Moderna COVID-19 Vaccine	80777-273-10 80777-0273-10	See FDA/CDC Guidance	1/1/2022
D1712	Janssen Covid-19 vaccine administration-booster dose	SARSCOV2 COVID-19 VAC Ad26 5x1010 VP/0.5mL IM DOSE BOOSTER	Janssen	Janssen COVID-19 Vaccine	59676-580-05 59676-0580-05	See FDA/CDC Guidance	1/1/2022
D1713	Pfizer-BioNTech Covid-19 vaccine administration tris-sucrose pediatric-first dose	SARSCOV2 COVID-19 VAC mRNA 10mcg/0.2mL tris-sucrose IM DOSE 1	Pfizer, Inc	Pfizer-BioNTech COVID-19 Vaccine	59267-1055-1 59267-1055-01	1st to 2nd dose: 21 days	1/1/2022
D1714	Pfizer-BioNTech Covid-19 vaccine administration tris-sucrose pediatric-second dose	SARSCOV2 COVID-19 VAC mRNA 10mcg/0.2mL tris-sucrose IM DOSE 2	Pfizer, Inc	Pfizer-BioNTech COVID-19 Vaccine	59267-1055-1 59267-1055-01	1st to 2nd dose: 21 days	1/1/2022